Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRR | Q9GZT4 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 10/20 | 0.47 |
| ▸ | PPARG | P37231 | 9/20 | 0.47 |
| ▸ | PPARD | Q03181 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383259 | 0.83 | SRR (0.50) | SRRPPARAPPARGPPARDFFAR1 | |
| SCHEMBL22264856 | 0.83 | PPARG (0.56) | SRRPPARAPPARGPPARDFFAR1 | |
| SCHEMBL22264858 | 0.83 | PPARG (0.56) | SRRPPARAPPARGPPARDFFAR1 | |
| SCHEMBL31321016 | 0.83 | PPARG (0.56) | SRRPPARAPPARGPPARDFFAR1 | |
| SCHEMBL9628212 | 0.81 | SRR (0.70) | SRRPPARAPPARGPPARD | |
| SCHEMBL2517934 | 0.81 | SRR (0.70) | SRRPPARAPPARGPPARD | |
| SCHEMBL16877217 | 0.81 | SRR (0.70) | SRRPPARAPPARGPPARD | |
| SCHEMBL23933856 | 0.81 | PPARA (0.54) | SRRPPARAPPARGPPARD | |
| SCHEMBL757308 | 0.81 | SRR (0.53) | SRRPPARAPPARGPPARDFFAR1 | |
| SCHEMBL23933859 | 0.81 | PPARA (0.54) | SRRPPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773101-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773101-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2020154492-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773101-B2 | GPR35 modulators | GPR35, GPR55, GPR65 | SRR 3009/4885PPARA 87/4885PPARG 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.